Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. has reported developments tied to molecular genetics diagnostics for early cancer detection and a later corporate transition to the Quantum Cyber name and QUCY ticker. Its company updates have centered on ColoAlert, a non-invasive colorectal cancer screening test marketed in Europe, and PancAlert, an early-stage pancreatic cancer screening candidate using PCR-based multiplex detection of molecular-genetic biomarkers in blood and stool samples.
Recurring news themes include clinical-study and conference disclosures for colorectal and pancreatic cancer detection, commercial distribution and digital-health partnerships, financing activity, strategic updates, board governance changes, and Nasdaq ticker matters.
BERKELEY, Calif. and MAINZ, Germany, Dec. 20, 2022 - Mainz Biomed (NASDAQ:MYNZ) announced the enrollment of its first patient in the eAArly DETECT study, part of the ColoFuture initiative. This study evaluates novel mRNA biomarkers to enhance the ColoAlert test for colorectal cancer (CRC), targeting advanced adenomas. Enrollment is expected to conclude in Q1 2023, with results anticipated in 1H 2023. The study aims to improve diagnostic sensitivity and specificity, vital in CRC prevention. The company is also preparing for its U.S. pivotal study, ReconAAsense, set to begin in 2023.
Mainz Biomed has received approval for its pivotal study, ReconAAsense, aimed at evaluating the clinical performance of its colorectal cancer detection test. The study will enroll approximately 15,000 subjects across 150 sites in the U.S., with results expected in 2025. This study is crucial for obtaining FDA marketing authorization and enhancing the technical profile of Mainz Biomed's tests for detecting advanced adenomas, which can lead to colorectal cancer. The eAArly DETECT study aims to integrate novel biomarker technology to improve diagnostic sensitivity.
Mainz Biomed (NASDAQ:MYNZ) has appointed Amy Levin as Vice President of Regulatory Affairs, effective immediately. Levin brings over 20 years of regulatory experience from Roche, where she significantly contributed to international regulatory strategies. Her role will focus on guiding the FDA submission process for ColoAlert, a DNA-based test for colorectal cancer. CEO Guido Baechler praised her strategic thinking and experience, which are crucial as the company aims for operational excellence and regulatory compliance in clinical trials.
Mainz Biomed NV (NASDAQ:MYNZ) has announced that its executive team will participate in two significant conferences: the Deutsches Eigenkapitalforum 2022 in Frankfurt from November 28-30 and Cantor Fitzgerald’s Medical & Aesthetic Dermatology Conference in Miami on December 8, 2022. At the Eigenkapitalforum, a presentation is scheduled for November 29 at 9:30 a.m. CET. The Cantor Fitzgerald event will feature one-on-one meetings with industry leaders. Mainz Biomed is known for its early cancer detection solutions, notably ColoAlert, aimed at colorectal cancer screening.
Mainz Biomed NV (NASDAQ:MYNZ) has initiated the eAArly DETECT study, expanding its ColoFuture project into the U.S. The study focuses on integrating novel mRNA biomarkers into its ColoAlert test for colorectal cancer (CRC). Enrollment is expected to finish by Q1 2023, with results anticipated in the first half of 2023. These biomarkers aim to enhance detection of advanced adenomas, a pre-cancerous condition linked to CRC. The study could expedite the U.S. pivotal study, which is set to begin later this year, potentially transforming self-administered CRC screening.
Mainz Biomed (NASDAQ:MYNZ) provided a Q3 2022 update highlighting key developments. The company launched its ColoAlert test in Italy and the UAE, targeting colorectal cancer detection. The ongoing ColoFuture study aims to enhance ColoAlert's capabilities and is on track for results in H1 2023. Mainz Biomed is also preparing for a pivotal U.S. clinical trial expected to start in Q4 2022, with results anticipated in 2025. A new Medical Advisory Board was formed to support product development. These initiatives signify Mainz Biomed's commitment to advancing cancer diagnostics.
Mainz Biomed NV (NASDAQ:MYNZ) has nominated Dr. Heiner Dreismann as Chairman of the Board and Gregory Tibbitts to its Board of Directors. The extraordinary general meeting is set for the week of December 12, 2022, to vote on their appointments. Dr. Dreismann brings over 35 years of diagnostics experience, having previously served as Roche Molecular Diagnostics CEO. Mr. Tibbitts, a CPA with 30 years in financial strategy, has extensive experience in the life sciences sector. Their appointments aim to strengthen Mainz Biomed's strategic and financial governance, particularly as it prepares for a pivotal U.S. clinical trial for its ColoAlert product.
Mainz Biomed N.V. (NASDAQ:MYNZ) announced the appointment of Dr. Douglas K. Rex to its Medical Advisory Board to support the U.S. pivotal trial for its colorectal cancer detection test, ColoAlert. Dr. Rex, a leading expert in colorectal cancer screening, brings extensive experience and credentials to the board. Mainz is currently marketing ColoAlert in Europe and the UAE, with plans for U.S. regulatory approval. The pivotal trial is on track to commence in 2022, aiming to capitalize on a $3.7 billion annual market opportunity among Americans aged 50 and older.
Mainz Biomed (NASDAQ:MYNZ) reported a 127% year-over-year increase in ColoAlert revenue, totaling $238,255 for the six months ended June 30, 2022.
The company achieved a mid-year cash balance of $26 million and initiated key international partnerships. The U.S. pivotal clinical trial for ColoAlert is set to start in Q4 2022, following supportive FDA feedback. However, Mainz recorded a net loss of $12.6 million and a gross profit decline, emphasizing increased operating expenses.
Mainz Biomed, a molecular genetics diagnostic company, announced participation in the H.C. Wainwright Annual Global Investment Conference from September 12-14, 2022, in New York City. CFO Bill Caragol will represent the company at this prestigious event. Mainz Biomed specializes in early cancer detection, particularly colorectal cancer, through its product ColoAlert. This non-invasive test boasts high sensitivity and specificity, providing a crucial tool for early diagnosis and intervention in colorectal cancer, a leading cause of cancer mortality.